Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GLRB 2743 GLYCINE CHEMBL773 DrugBank 16884688
GLRB 2743 NIFEDIPINE CHEMBL193 antagonist GuideToPharmacologyInteractions
GLRB 2743 PICROTOXININ CHEMBL47244 channel blocker GuideToPharmacologyInteractions
GLRB 2743 PANITUMUMAB CHEMBL1201827 antagonist TTD
GLRB 2743 ZINC ION CHEMBL1236970 allosteric modulator GuideToPharmacologyInteractions
GLRB 2743 BILOBALIDE CHEMBL133266 antagonist GuideToPharmacologyInteractions
GLRB 2743 CHEMBL1179605 CHEMBL1179605 antagonist GuideToPharmacologyInteractions
GLRB 2743 TROPISETRON CHEMBL56564 antagonist GuideToPharmacologyInteractions
GLRB 2743 DESFLURANE CHEMBL1200733 ChemblInteractions
GLRB 2743 HALOTHANE CHEMBL931 ChemblInteractions
GLRB 2743 ENFLURANE CHEMBL1257 ChemblInteractions
GLRB 2743 PICROTIN CHEMBL478523 channel blocker GuideToPharmacologyInteractions
GLRB 2743 ISOFLURANE CHEMBL1256 ChemblInteractions
GLRB 2743 SEVOFLURANE CHEMBL1200694 ChemblInteractions
GLRB 2743 MINOXIDIL CHEMBL802 antagonist GuideToPharmacologyInteractions
GLRB 2743 PICROTOXIN CHEMBL1908342 channel blocker GuideToPharmacologyInteractions
GLRB 2743 METHOXYFLURANE CHEMBL1341 agonist ChemblInteractions
GLRB 2743 GW468816 CHEMBL1207366 antagonist TTD
GLRB 2743 LINDANE CHEMBL15891 antagonist DrugBank 20600211, 12614680

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GLRB rs17035723 T acamprosate efficacy no Tag SNPs (518 total) were selected within genes associated with alcoholism as well as genes encoding enzymes involved in glycine metabolism, glycine transporters, subunits of glycine receptors, NMDA receptors, genes involved in glutamate reuptake, synthesis or degradation and genes with reported associations with acamprosate treatment outcomes in human or animal studies. The length of time to first alcohol use “survival analysis method” was used to examine associations between clinical variables and genetic markers with efficacy of acomprasate (its ability to length the duration of abstinence from alcohol). The analyses were replicated in a subset of 110 participants from PREDICT, a double-blind randomized controlled trial that compared treatment outcomes including length of abstinence among alcohol- dependent subjects of German descent recruited from inpatient facilities and treated with acamprosate, naltrexone or placebo for 3 months. rs17035723 A allele was nominally associated with shorter abstinence after Bonferroni correction for the number of SNPs included in the analyses in the male only cohort (N=148) of the discovery sample (P = 9.8 × 10 - 5, corrected P = 0.0507). Allele T is not associated with response to acamprosate in people with Alcoholism as compared to allele C. 25290263 1184988646